SUDO-550, an oral TYK2 inhibitor being developed by Sudo Biosciences, was found to be safe, well-tolerated, and to fully reach the brain in a first-in-human clinical trial involving healthy volunteers, […]
The post Experimental MS therapy safely reaches brain in first human trial appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com